Clovis' (CLVS) Rociletinib to Face FDA Advisory Panel in April

Clovis Oncology, Inc.CLVS announced that the new drug application (NDA) for its lead pipeline candidate, rociletinib, is scheduled to be reviewed by the FDA's Oncologic Drugs Advisory Committee (ODAC) on Apr 12, 2016. The company's shares were up almost